Biomarkers identification for PML monitoring, during Natalizumab (Tysabri ®) treatment in Relapsing-Remitting Multiple Sclerosis
This article review aims to list some biomarkers that have been proposed to evaluate the safety of natalizumab therapy.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Brain | Clinical Trials | Disability | Marketing | Multiple Sclerosis | Neurology | Study | Tysabri